Directorate Change

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery (“MIS”), announces the following Board changes:

After 9 years in executive roles at Surgical Innovations, David Marsh has decided to step down from his role as Chief Executive Officer (“CEO”) and will transition to the role of Non-Executive Director of the Company on 1 October 2026. As part of this transition, David will continue to support the new CEO, including through key relationships and business development opportunities. David joined the Group following Surgical Innovations’ acquisition of Elemental Healthcare, the company he jointly founded.

Alex Warnock will join the Board of the Company as CEO on the same date. Alex is a commercially driven public company board director with over 25 years’ experience in senior operational roles. Alex brings extensive international experience driving transformational growth and shareholder value across high-tech manufacturing, Photonics and regulated MedTech sectors. He was previously Group Managing Director of SDI Group plc and before that Chief Operating Officer at Foster & Freeman Ltd, Gooch & Housego plc, and Optos plc. He has a proven track record in delivering profitable revenue growth and operational excellence, developing new products, and commercialising complex clinical technologies with an entrepreneurial, hands-on approach to scaling innovative smaller enterprises and navigating highly regulated global markets.

Commenting on the Board changes, Roy Davis, Chairman of Surgical Innovations plc said: "David has played an important role over the last 20 years in founding the Elemental business, as CEO of the Surgical Innovations team and as a Board member. I would like to thank David for his outstanding commitment to the business and look forward to his continued involvement as a Non-Executive Director and advisor going forward.

“We are delighted to welcome Alex on board, and we look forward to him leading the Surgical Innovations team. He has been instrumental in developing industry-leading products in his past roles and has a track record of delivery. Alex brings significant commercial and operational expertise to the business including successful new product launches. We believe Alex has the right skillset to execute on our future plans and deliver long term value to shareholders."

David Marsh commented: "I am pleased to be able to transition from an executive to a Non-Executive role with Surgical Innovations. I am incredibly proud of what we have achieved and remain confident in the opportunities the business has ahead of it. I look forward to being able to support Alex and to continue to contribute to the business as a Non-Executive Director."

Alex Warnock, incoming Chief Executive Officer commented: "I am excited to be joining Surgical Innovations Group. The business has significant potential and a broad range of minimally invasive surgical products with exciting growth opportunities in new markets. I'm looking forward to working with Roy, the rest of the Board, and the Surgical Innovations team to deliver on the opportunity ahead of us."

Alex Warnock (aged 61) is currently, or has during the past five years, been a director of the following companies

Save as set out in this announcement there are no further details to be disclosed in accordance with Rule 17 and Schedule Two Paragraph (g) of the AIM Rule for Companies.